NCT03099356View on ClinicalTrials.gov

Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

April 27, 2017

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Metastatic Thyroid Cancer
Interventions
DRUG

Cyclophosphamide

Cyclophosphamide 100 mg, PO, days 1-5 and 15-19

DRUG

Sirolimus

Sirolimus 4 mg, PO, days 1-28

Trial Locations (1)

48109

RECRUITING

University of Michigan Cancer Center, Ann Arbor

All Listed Sponsors
lead

University of Michigan Rogel Cancer Center

OTHER